Naveen Anand Seecheran

Naveen Anand Seecheran

Auto-generated profile, based on publicly available information

Naveen Anand Seecheran

University of the West Indies

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
DCDavide Capodanno
Davide Capodanno
APAasita Patel
Aasita Patel
KDKodlipet Dharmashankar
Kodlipet Dharmashankar
JFJose Luis Ferreiro
Jose Luis Ferreiro
MUMasafumi Ueno
Masafumi Ueno
DADominick J. Angiolillo
Dominick J. Angiolillo
Background—: Patients with type 2 diabetes mellitus (T2DM) have reduced aspirin-induced pharmacodynamic effects. This may be attributed to increased platelet turnover rates resulting in an increased proportion of non–aspirin-inhibited platelets during the daily dosing interval. The hypothesis of this study was that an increase in the frequency of drug administration [twice daily (bid) versus once daily (od)] may provide more effective platelet inhibition in T2DM patients. Methods and Results—: T2DM patients with stable coronary artery disease were prospectively recruited. Patients modified their aspirin regimen on a weekly basis according to the following scheme: 81 mg/od, 81 mg/bid, 162 mg/od, 162 mg/bid, and 325 mg/od. Pharmacodynamic assessments included light-transmittance aggregometry after arachidonic acid, collagen and adenosine diphosphate stimuli; VerifyNow-Aspirin assay; and serum thromboxane B 2 (TXB 2 ) levels. Twenty patients were analyzed. All patients were sensitive and compliant to aspirin irrespective of dose, as assessed by arachidonic acid–induced aggregation. When aspirin was administered once daily, there was no significant effect on platelet reactivity by increasing the once-daily dosing using aspirin-sensitive assays (collagen-induced aggregation and VerifyNow-Aspirin). An increase in aspirin dose by means of a second daily administration was associated with a significant reduction in platelet reactivity assessed by collagen-induced aggregation and VerifyNow-Aspirin between 81 mg/od and 81 mg/bid ( P <0.05 for both assays) and between 81 mg/od and 162 mg/bid ( P <0.05 for both assays). There was no impact of aspirin dosing regimens on adenosine diphosphate–induced aggregation. A dose-dependent effect of aspirin was observed on serum TXB 2 levels ( P =0.003). Conclusions—: Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB 2 levels. The clinical implications of a modified aspirin regimen tailored to T2DM patients warrant further investigation. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01201785.

1 April 2014 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
DSDavid J. Schneider
David J. Schneider
ZAZubin Agarwal
Zubin Agarwal
NSNaveen Seecheran
Naveen Seecheran
FKFriederike K. Keating
Friederike K. Keating
PGProspero Gogo
Prospero Gogo

1 January 2015 in Coronary Artery Disease
Verified
Journal Article
Closed access
DSDavid J. Schneider
David J. Schneider
NSNaveen Seecheran
Naveen Seecheran
SRSyed Sadi Raza
Syed Sadi Raza
FKFriederike K. Keating
Friederike K. Keating
PGProspero Gogo
Prospero Gogo
The aim of this study was to determine the impact of cangrelor and prasugrel on the pharmacodynamic effects of each agent. The development of an intravenous P2Y12 antagonist necessitates transition between intravenous and oral therapy. Patients (n=15) with stable coronary artery disease who were taking 81 mg aspirin daily were recruited. On study day 1, they received a bolus plus 2-h infusion of cangrelor plus a 60 mg dose of prasugrel at 1 h (n=3), 1.5 h (n=6), 2 h (n=3), or 2.5 h (n=3). Pharmacodynamic effects (light transmission platelet aggregation in response to 20 μmol/l ADP, VerifyNow, and flow cytometry) were assessed during and after the cangrelor infusion. Patients took 10 mg of prasugrel daily for either 5 days (n=6) or 6 days (n=6). On study day 8, pharmacodynamic effects were assessed before and during a bolus plus 2-h infusion of cangrelor. During cangrelor infusion (days 1 and 8), extensive inhibition of platelet function, reflected by limited residual platelet reactivity, was apparent. On day 1, transient (limited to the first hour after cangrelor was stopped) but substantial (>50%) recovery of platelet reactivity was observed. This recovery was attenuated when prasugrel was given at 1.5 h (30 min before cangrelor was stopped). Prasugrel did not alter the antiplatelet effects of cangrelor, but transient recovery of platelet reactivity was apparent during the transition from cangrelor to prasugrel. Recovery of platelet reactivity was limited when prasugrel was administered 30 min before the end of the cangrelor infusion.

1 January 2020 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
PDF file
RSRajeev Seecheran
Rajeev Seecheran
RNRoshni Narayansingh
Roshni Narayansingh
SGStanley Giddings
Stanley Giddings
MRMarlon Rampaul
Marlon Rampaul
KFKurt Furlonge
Kurt Furlonge
NSNaveen Anand Seecheran
Naveen Anand Seecheran
The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) that has significant potential cardiovascular implications for patients. These include myocarditis, acute coronary syndromes, cardiac arrhythmias, cardiomyopathies with heart failure and cardiogenic shock, and venous thromboembolic events. We describe a Caribbean-Black gentleman with COVID-19 infection presenting with atrial arrhythmias, namely, atrial flutter and atrial fibrillation, which resolved with rate and rhythm control strategies, and supportive care.

10 November 2012 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
ATAntonio Tello-Montoliu
Antonio Tello-Montoliu
NSNaveen A. Seecheran
Naveen A. Seecheran
Dominick Joseph AngiolilloDominick Joseph Angiolillo
Dominick Joseph Angiolillo

1 June 2011 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
JFJose Luis Ferreiro
Jose Luis Ferreiro
MUMasafumi Ueno
Masafumi Ueno
STSalvatore D. Tomasello
Salvatore D. Tomasello
DCDavide Capodanno
Davide Capodanno
BDBhaloo Desai
Bhaloo Desai
DADominick J. Angiolillo
Dominick J. Angiolillo
Background—: Safety concerns have recently emerged based on a drug interaction between clopidogrel and proton pump inhibitors leading to reduced pharmacodynamic effects. However, whether such drug interaction is a class effect or a drug effect and if this can be modulated by timing of drug administration remains a matter of debate. The aim of this study was to assess the impact of high-dose pantoprazole therapy, a proton pump inhibitor with low potential to interfere with clopidogrel metabolism, administered concomitantly or staggered, on clopidogrel-mediated pharmacodynamic effects. Methods and Results—: This was a prospective, randomized, crossover study conducted in 20 healthy volunteers. Subjects were randomly assigned to receive pantoprazole (80 mg daily) administered concomitantly (CONC) or staggered by 8 to 12 hours (STAG) for 1 week on a background of clopidogrel therapy (600-mg loading dose followed by a 75-mg maintenance dose during all phases) in a crossover fashion with a 2- to 4-week washout period between treatments. All subjects had a 1-week treatment phase with a clopidogrel-only regimen with a 2- to 4-week washout period from randomization sequence. Platelet function was assessed by flow cytometric analysis of the status of phosphorylation of the vasodilator-stimulated phosphoprotein, light transmittance aggregometry after adenosine diphosphate stimuli, and VerifyNow P2Y 12 system at 3 time points: baseline, 24 hours after loading dose, and 1 week after maintenance dose. The primary end point was the comparison of P2Y 12 reactivity index assessed by vasodilator-stimulated phosphoprotein at 1 week. After 1 week, there were no significant difference in P2Y 12 reactivity index between the CONC and STAG regimens (least-squares mean±SEM, 56.0±3.9% versus 56.1±3.9%; P =0.974), as well as when compared with the clopidogrel-only regimen (61.0±3.9%; P =0.100 versus CONC and P =0.107 versus STAG). Further, no differences were observed at baseline and 24 hours between regimens. Concordant results were obtained by light transmittance aggregometry and VerifyNow P2Y 12 assays. Conclusions—: Pantoprazole therapy used at high doses is not associated with modulation of the pharmacodynamic effects of clopidogrel, irrespective of timing of drug administration. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01170533.